二甲双胍
医学
药理学
癌症
糖尿病
重症监护医学
肿瘤科
内科学
内分泌学
作者
Wei Mu,Yunyun Jiang,Guoqiang Liang,Yue Feng,Falin Qu
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2022-11-07
卷期号:24 (1): 41-54
被引量:9
标识
DOI:10.2174/1389450124666221104094918
摘要
Metformin is a widely used drug in patients with type 2 diabetes mellitus. Metformin inhibits hepatic gluconeogenesis and increases glucose utilization in peripheral tissues. In recent years, several studies have shown that metformin is a potential therapeutic agent against cancer, alone or combined with other anticancer treatments. Metformin mainly activates the AMPK complex and regulates intracellular energy status, inhibiting the mitochondrial respiratory chain complex I and reducing the production of reactive oxygen species. Other anticancer targets of metformin are specific transcription factors inhibiting cell proliferation, promoting apoptosis and reducing drug resistance. In addition, metformin modulates tumor cells' response to anticancer treatments, favoring the activity of T cells. In diabetic patients, metformin reduces the occurrence of cancer and improves the prognosis and efficacy of anticancer treatments. In this review, we provided a comprehensive perspective of metformin as an anticancer drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI